Clopidogrel is a prodrug. It inhibits platelet activation and aggregation by irreversibly binding its active metabolites to P2Y12 ADP receptors on platelets. A dose-dependent inhibition of platelet aggregation can be observed 2 hours after a single oral administration. A repeated daily dose of 75 mg inhibited ADP-induced platelet aggregation on the first day, and the inhibition reached a steady state between the 3rd and the 7th day.
Dosage & Administration of Clotinil 75 Tablet
coronary syndrome: For patients who need to exert antiplatelet effects within a
few hours, start clopidogrel with a single oral loading dose of 300 mg (4
tablets) and then continue to take 75 mg once daily. Starting without a loading
dose will delay the onset of antiplatelet effects for several days.
MI, recent stroke, or established peripheral artery disease: 75 mg orally once
daily with no loading dose.
Oral with or without food.
Interactions of Clotinil 75 Tablet
warfarin, selective serotonin and norepinephrine reuptake inhibitors (SSRIs,
SNRIs): increase the risk of bleeding
inhibitors (omeprazole or esomeprazole): avoid simultaneous use of Ogilvy
Prazole or Esomeprazole
Repaglinide (using Repcomit2C substrate) increases the plasma concentration of Repaglinide
Clopidogrel is contraindicated in the following situations: Allergic to any component of the drug or product. Active pathological bleeding, such as peptic ulcer or intracranial hemorrhage.
Side-Effects of Clotinil 75 Tablet
is usually a well-tolerated drug.
side effects: bleeding, diarrhea, gastrointestinal discomfort, bleeding, skin
Rare side effects: Acquired hemophilia, anemia, angioedema, joint pain, arthritis, bone marrow disease.
Pregnancy & Lactation
There is no adequate and well-controlled study of pregnant women. It should be used during pregnancy only when clearly necessary. It is not known whether clopidogrel is excreted in human milk. The importance of the drug to the mother should be considered and a decision made to stop breastfeeding or discontinue the drug.
Precautions & Warnings
Since it is a prodrug, the metabolism of its active metabolites is affected by CYP2C19 (weak metabolizer) gene mutations and drugs that inhibit CYP2C19 (such as omeprazole and esomeprazole).
use of these drugs and CYP2C19 weak metabolizers may reduce the antiplatelet
activity of clopidogrel.
it inhibits platelet aggregation during the entire life cycle (710 days) of
platelets, it may increase the risk of bleeding. In order to restore
hemostasis, platelet transfusion within 4 hours after the loading dose or
within 2 hours after the maintenance dose may be less effective.
Discontinuation of clopidogrel increases the risk of cardiovascular events.
Discontinue medication 5 days prior to elective surgery due to risk of severe bleeding.
was restored immediately after hemostasis.
thrombocytopenic purpura (TTP) is reported to require urgent treatment,
including plasma exchange (plasma exchange).
In patients receiving clopidogrel or patients with a history of allergies to other thienopyridines, allergies, including rash, angioedema, or haematological reactions have been reported.
Keep below 30°C temperature in a dry place. Protected from light. Do not freeze. Keep out of the reach of children.